시장보고서

상품코드

1709467

호흡기세포융합바이러스 치료제 시장 : 치료제 유형별, 제형별, 연령층별, 유통 채널별, 국가별, 지역별 - 세계 산업 분석, 시장 규모 및 점유율, 예측(2025-2032년)

Respiratory Syncytial Virus Therapeutics Market, By Treatment Type, By Dosage Form, By Age Group, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

발행일: 2025년 03월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 299 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

호흡기세포융합바이러스 치료제 시장 규모는 2024년에 15억 9,032만 달러에 달하며, 2025-2032년에 CAGR 15.50%로 확대

진단 기술의 발전으로 조기 발견 및 적시 개입 지원 북미와 유럽은 강력한 의료 인프라와 높은 인지도로 인해 우위를 점하고 있지만, 신흥 국가에서는 도입이 확대되고 있습니다. 시장의 성장은 생명공학 기업과 의료기관의 공동연구에 의해 더욱 지원되고 있습니다. 비용 효율적인 치료법의 도입은 전 세계에서 접근성을 향상시키고 더 나은 질병 관리를 보장할 것으로 기대됩니다.

호흡기세포융합바이러스 치료제 시장 역학

영유아의 RSV(호흡기세포융합바이러스) 예방을 위한 장시간 지속형 모노클로널 항체 도입 확대

영유아의 RSV 예방을 위한 지속형 단클론 항체의 채택 증가는 RSV 치료제 시장의 주요 촉진요인으로, 팔리비주맙과 같은 기존 단클론 항체는 매달 투여해야 하므로 접근성 및 순응도가 제한적이었습니다. 그러나 닐세비맙과 같은 새로운 장시간 작용하는 항체는 1회 투여로 장기간의 예방 효과를 얻을 수 있으며, 편리하고 비용 효율적입니다. 정부와 의료기관은 RSV로 인한 입원을 줄이기 위해 고위험군 영아에게 이러한 치료를 적극 권장하고 있습니다. 신생아 및 미숙아에서 RSV 감염의 부담이 크기 때문에 예방접종 프로그램이 확대되고 있습니다. 또한 지속형 단클론 항체에 대한 규제 당국의 승인과 자금 지원으로 인해 선진국 및 신흥 시장에서의 접근성이 높아지고 있습니다. 이러한 치료법이 일상적인 영유아 치료에 통합되면서 시장 성장의 큰 원동력이 될 것으로 예상됩니다.

호흡기세포융합바이러스 치료제 시장 : 주요 고려사항

당사의 리서치 애널리스트들이 공유한 분석에 따르면 세계 시장은 예측 기간(2025-2032년) 동안 약 15.50%의 연평균 복합 성장률(CAGR)로 매년 성장할 것으로 예상됩니다.

치료제 유형별로 보면 모노클로널 항체가 2024년 가장 큰 시장 점유율을 차지했습니다.

제형별로는 주사제가 2024년 주요 제형으로 부상했습니다.

연령대별로는 영유아가 2024년 주요 연령층입니다.

유통 채널별로는 2024년 병원 및 클리닉이 유통 채널 중 가장 높은 비중을 차지할 것으로 예상됩니다.

지역별로는 북미가 2024년 주요 수입원입니다.

호흡기세포융합바이러스 치료제 시장 : 세분화 분석

호흡기세포융합바이러스 치료제 세계 시장은 치료제 유형, 투여 형태, 연령대, 유통 채널, 지역에 따라 세분화됩니다.

시장은 치료제의 유형에 따라 항바이러스제, 모노클로널 항체, 백신 등 세 가지로 분류됩니다. 단클론 항체 부문은 호흡기세포융합바이러스(RSV) 치료제 시장을 독점하고 있으며, 특히 영유아와 노인과 같은 고위험군의 중증 RSV 감염 예방에 효과적이기 때문에 시장을 주도하고 있습니다. 팔리비주맙은 수년 전부터 널리 사용되어 왔으며, 최근 닐세비맙과 같은 장시간 작용하는 모노클로널 항체가 승인되면서 이 분야가 더욱 강화되었습니다. 이러한 치료는 수동 면역을 제공하고 RSV로 인한 입원 및 합병증을 감소시키며, RSV 감염의 부담이 증가하고 있으며, 취약한 집단에 대한 정부 권장 사항과 함께 단클론 항체 사용을 권장하고 있으며, 수요를 촉진하고 있습니다. 제약회사들은 효능이 향상되고 작용 시간이 연장된 차세대 모노클로널 항체 개발에 지속적으로 투자하고 있습니다. 또한 이러한 치료제의 높은 가격이 시장 매출에 크게 기여하고 있습니다. 북미와 유럽은 강력한 의료 인프라와 상환 정책으로 인해 채택이 빠르게 진행되고 있습니다. 새로운 항체 제제가 규제 당국의 승인을 받음에 따라 이 부문은 RSV 치료제 시장에서 우위를 유지할 것으로 예상됩니다.

시장은 제형에 따라 경구제, 주사제, 흡입제의 세 가지 범주로 분류됩니다. 주로 주사로 투여되는 단클론 항체 및 백신이 널리 사용되고 있으므로 주사제 부문이 호흡기세포융합바이러스(RSV) 치료제 시장을 주도하고 있습니다. 팔리비주맙과 닐세비맙과 같은 단클론 항체 및 노인들을 위해 새로 승인된 RSV 백신은 효과적인 전달을 위해 주사제형에 의존하고 있습니다. 이 투여 경로는 정확한 투여, 빠른 흡수, 장기간의 보호를 보장하므로 고위험군에게 선호되는 선택이 될 수 있습니다. 영유아와 노년층에서 심각한 RSV 감염의 발생률이 증가함에 따라 주사 치료법의 채택이 증가하고 있습니다. 또한 정부 예방접종 프로그램과 병원 프로토콜이 RSV 주사 요법을 지지하고 있으며, 이 분야에 더욱 힘을 실어주고 있습니다. 북미와 유럽은 의료 인프라가 잘 갖추어져 있고 백신 접종률이 높기 때문에 RSV 치료제 주사제 분야에서 선두를 달리고 있습니다. 더 많은 지속형 단클론 항체 및 RSV 백신이 승인됨에 따라 주사제 부문이 우위를 유지할 것으로 예상됩니다.

호흡기세포융합바이러스 치료제 시장 : 지역별 분석

북미가 호흡기세포융합바이러스(RSV) 치료제 시장을 주도하고 있는 것은 높은 인지도, 탄탄한 의료 인프라, 단클론 항체 및 백신의 광범위한 채택에 기인합니다. 미국은 정부의 예방접종 프로그램 지원과 닐세비맙(Nirsevimab) 및 노인용 RSV 백신과 같은 첨단 RSV 치료제에 대한 규제 당국의 승인으로 이 지역을 선도하고 있습니다. 영유아 및 노인의 RSV 관련 입원 환자 수가 증가함에 따라 효과적인 치료법에 대한 수요가 증가하고 있습니다. 또한 주요 제약사들은 차세대 단일 클론 항체를 도입하기 위해 연구개발에 투자하고 있습니다. 유리한 상환 정책과 높은 의료비 지출은 이 지역 시장 성장을 더욱 촉진하고 있습니다.

미국이 호흡기세포융합바이러스(RSV) 치료제 시장에서 가장 큰 점유율을 차지하고 있는 것은 첨단화된 의료 인프라, 높은 질병 인식, 정부의 강력한 지원, CDC와 FDA가 노인용 RSV 백신과 영아 예방용 닐세비맙과 같은 지속형 단클론 항체를 승인하여 보급을 촉진하고 있기 때문입니다. RSV 관련 입원 환자, 특히 영유아와 노인 증가로 인해 효과적인 치료법에 대한 수요가 증가하고 있습니다. 정부 지원 예방접종 프로그램 및 환급 정책은 시장 성장을 더욱 촉진하고 있습니다. 또한 제약회사들은 차세대 RSV 치료제를 개발하기 위해 연구 및 임상시험에 많은 투자를 하고 있습니다. 높은 의료비 지출과 강력한 규제 프레임워크는 시장의 지속적인 확장을 보장하고 있습니다.

호흡기세포융합바이러스 치료제 시장 : 경쟁 구도

호흡기세포융합바이러스(RSV) 치료제 시장의 경쟁 환경은 치열한 연구개발(R&D) 노력, 전략적 제휴, 규제 당국의 승인으로 특징지어집니다. 주요 기업은 RSV 감염 증가에 대응하기 위해 단클론 항체, 백신, 항바이러스제 개발에 주력하고 있습니다. AstraZeneca, Sanofi, Pfizer, GSK, Moderna는 혁신적인 RSV 치료제를 출시했거나 개발 중으로 시장을 독점하고 있습니다.

화이자가 RSV 항바이러스제 개발을 위해 ReViral을 인수한 것처럼 주요 기업은 전략적 제휴와 인수를 통해 제품 포트폴리오를 확장하고 있습니다. 닐세비맙과 같은 지속형 모노클로널 항체 및 노인용 RSV 백신이 승인되면서 경쟁이 치열해지고 있습니다. RSV 예방 및 치료에 대한 수요가 증가함에 따라 신규 진입과 첨단 치료 솔루션이 등장하면서 경쟁 구도는 더욱 치열해질 것으로 예상됩니다.

서론
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 네덜란드
- 스웨덴
- 러시아
- 폴란드
- 기타
아시아태평양(APAC)
- 개요
- 아시아태평양의 주요 제조업체
- 중국
- 인도
- 일본
- 한국
- 호주
- 인도네시아
- 태국
- 필리핀
- 기타
라틴아메리카(LATAM)
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카(MEA)
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 튀르키예
- 알제리
- 이집트
- 기타

제12장 주요 벤더 분석 : 호흡기세포융합바이러스 치료제 업계

경쟁 대시보드
- 경쟁 벤치마킹
- 경쟁 포지셔닝
기업 개요
- AstraZeneca plc
- Sanofi SA
- Pfizer Inc.
- Moderna, Inc.
- GSK plc
- Merck & Co., Inc.
- Johnson &Johnson
- Novavax, Inc.
- Bavarian Nordic A/S
- Enanta Pharmaceuticals, Inc.
- BioNTech SE
- Meissa Vaccines, Inc.
- Codagenix, Inc.
- Alnylam Pharmaceuticals, Inc.
- Vaxart, Inc.
- Icosavax, Inc.

제13장 AnalystView의 전방위적 분석

KSA 25.05.07

REPORT HIGHLIGHT

Respiratory Syncytial Virus Therapeutics Market size was valued at US$ 1,590.32 Million in 2024, expanding at a CAGR of 15.50% from 2025 to 2032.

The Respiratory Syncytial Virus (RSV) therapeutics market focuses on treatments and preventive solutions for RSV infections, which primarily affect infants, older adults, and immunocompromised individuals. This market includes antiviral drugs, monoclonal antibodies, and vaccines aimed at reducing disease severity and transmission. The increasing prevalence of RSV, along with rising hospitalizations, has driven demand for effective therapies. Governments and pharmaceutical companies are investing in research to develop advanced treatments, including long-acting monoclonal antibodies and novel antivirals. Regulatory approvals for RSV vaccines, especially for high-risk groups, have expanded the market.

Advancements in diagnostic techniques support early detection and timely intervention. North America and Europe dominate due to strong healthcare infrastructure and high awareness while emerging economies show growing adoption. Market growth is further supported by collaborations between biotech firms and healthcare organizations. The introduction of cost-effective therapies is expected to enhance accessibility worldwide, ensuring better disease management.

Respiratory Syncytial Virus Therapeutics Market- Market Dynamics

Increasing adoption of long-acting monoclonal antibodies for infant RSV protection.

The increasing adoption of long-acting monoclonal antibodies for infant RSV protection is a key driver of the RSV therapeutics market. Traditional monoclonal antibodies, such as Palivizumab, required monthly dosing, limiting their accessibility and compliance. However, newer long-acting antibodies like Nirsevimab offer extended protection with a single dose, making them more convenient and cost-effective. Governments and healthcare organizations are actively recommending these therapies for high-risk infants to reduce RSV-related hospitalizations. The high burden of RSV infections in newborns and premature babies has led to expanded immunization programs. Additionally, regulatory approvals and funding for long-acting monoclonal antibodies are increasing their availability in developed and emerging markets. As these therapies become more integrated into routine infant care, they are expected to drive market growth significantly.

Respiratory Syncytial Virus Therapeutics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 15.50% over the forecast period (2025-2032)

Based on Treatment Type segmentation, monoclonal antibodies were predicted to show maximum market share in the year 2024

Based on Dosage Form segmentation, injectable was the leading Dosage Form in 2024

Based on Age Group segmentation, Infants & Young Children was the leading Age Group in 2024

Based on Distribution Channel segmentation, Hospitals & Clinics was the leading Distribution Channel in 2024

based on region, North America was the leading revenue generator in 2024

Respiratory Syncytial Virus Therapeutics Market- Segmentation Analysis:

The Global Respiratory Syncytial Virus Therapeutics Market is segmented based on Treatment Type, Dosage Form, Age Group, Distribution Channel, and Region.

The market is divided into three categories based on Treatment Type: Antiviral Drugs, Monoclonal Antibodies, and Vaccines. The monoclonal antibodies segment dominates the Respiratory Syncytial Virus (RSV) therapeutics market due to their effectiveness in preventing severe RSV infections, especially in high-risk groups like infants and older adults. Palivizumab has been widely used for years, and the recent approval of long-acting monoclonal antibodies such as Nirsevimab has further strengthened this segment. These treatments provide passive immunity, reducing RSV-related hospitalizations and complications. The increasing burden of RSV infections, along with government recommendations for monoclonal antibody use in vulnerable populations, has fueled demand. Pharmaceutical companies continue to invest in developing next-generation monoclonal antibodies with improved efficacy and longer duration of action. Additionally, the high cost of these therapies contributes significantly to market revenue. North America and Europe lead in adoption due to strong healthcare infrastructure and reimbursement policies. As new antibody formulations receive regulatory approvals, this segment is expected to maintain its dominance in the RSV therapeutics market.

The market is divided into three categories based on Dosage Form: Oral, Injectable, and Inhalation. The injectable segment dominates the Respiratory Syncytial Virus (RSV) therapeutics market due to the widespread use of monoclonal antibodies and vaccines, which are primarily administered via injection. Monoclonal antibodies like Palivizumab and Nirsevimab, as well as newly approved RSV vaccines for older adults, rely on injectable formulations for effective delivery. This route ensures precise dosing, rapid absorption, and prolonged protection, making it the preferred choice for high-risk populations. The rising incidence of severe RSV infections among infants and older adults has led to increased adoption of injectable treatments. Additionally, government immunization programs and hospital protocols favor injectable RSV therapies, further boosting this segment. North America and Europe lead in injectable RSV therapeutics due to strong healthcare infrastructure and high vaccine coverage. As more long-acting monoclonal antibodies and RSV vaccines gain approval, the injectable segment is expected to maintain its dominance.

Respiratory Syncytial Virus Therapeutics Market- Geographical Insights

North America dominates the Respiratory Syncytial Virus (RSV) therapeutics market due to high awareness, strong healthcare infrastructure, and widespread adoption of monoclonal antibodies and vaccines. The U.S. leads the region, with government-backed immunization programs and regulatory approvals for advanced RSV therapies like Nirsevimab and RSV vaccines for older adults. Increasing RSV-related hospitalizations among infants and elderly populations have driven demand for effective treatments. Additionally, major pharmaceutical companies are investing in research and development to introduce next-generation monoclonal antibodies. Favorable reimbursement policies and high healthcare spending further support market growth in the region.

The United States holds the largest share of the Respiratory Syncytial Virus (RSV) therapeutics market due to its advanced healthcare infrastructure, high disease awareness, and strong government support. The CDC and FDA have approved RSV vaccines for older adults and long-acting monoclonal antibodies like Nirsevimab for infant protection, driving widespread adoption. Rising RSV-related hospitalizations, particularly among infants and the elderly, have increased demand for effective treatments. Government-backed immunization programs and reimbursement policies further boost market growth. Additionally, pharmaceutical companies are heavily investing in research and clinical trials to develop next-generation RSV therapeutics. The country's high healthcare spending and robust regulatory framework ensure continued market expansion.

Respiratory Syncytial Virus Therapeutics Market- Competitive Landscape:

The competitive landscape of the Respiratory Syncytial Virus (RSV) therapeutics market is characterized by intense research and development (R&D) efforts, strategic collaborations, and regulatory approvals. Leading pharmaceutical companies focus on developing monoclonal antibodies, vaccines, and antiviral drugs to address the growing burden of RSV infections. The market is dominated by AstraZeneca, Sanofi, Pfizer, GSK, and Moderna, which have introduced or are developing innovative RSV therapeutics.

Key players are leveraging strategic partnerships and acquisitions to expand their product portfolios, as seen in Pfizer's acquisition of ReViral for RSV antiviral development. The approval of long-acting monoclonal antibodies like Nirsevimab and RSV vaccines for older adults has intensified competition. Companies are also focusing on clinical trials, government collaborations, and pricing strategies to strengthen their market position. With increasing demand for RSV prevention and treatment, the competitive landscape is expected to evolve with new entrants and advanced therapeutic solutions.

Recent Developments:

In February 2024, GSK plc announced that the U.S. Food and Drug Administration (FDA) granted priority review for an application to expand the indication of its combined respiratory syncytial virus (RSV) vaccine to individuals aged 50 to 59 at higher risk of RSV illness.

In May 2023, Pfizer Inc. stated that the U.S. Food and Drug Administration (FDA) approved ABRYSVO, its bivalent RSV prefusion F (RSVpreF) vaccine, for preventing lower respiratory tract illness caused by RSV in individuals aged 60 and older. This strategy has contributed to the company's revenue growth.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

AstraZeneca plc
Sanofi S.A.
Pfizer Inc.
Moderna, Inc.
GSK plc
Merck & Co., Inc.
Johnson & Johnson
Novavax, Inc.
Bavarian Nordic A/S
Enanta Pharmaceuticals, Inc.
BioNTech SE
Meissa Vaccines, Inc.
Codagenix, Inc.
Alnylam Pharmaceuticals, Inc.
Vaxart, Inc.
Icosavax, Inc.

GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032

Antiviral Drugs
Monoclonal Antibodies
Vaccines

GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET, BY DOSAGE FORM- MARKET ANALYSIS, 2019 - 2032

Oral
Injectable
Inhalation

GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET, BY AGE GROUP- MARKET ANALYSIS, 2019 - 2032

Infants & Young Children
Adults
Older Adults (65+ years)

GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

Hospitals & Clinics
Retail Pharmacies
Online Pharmacies

GLOBAL RESPIRATORY SYNCYTIAL VIRUS THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Respiratory Syncytial Virus Therapeutics Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Respiratory Syncytial Virus Therapeutics Market Snippet by Treatment Type
- 2.1.2. Respiratory Syncytial Virus Therapeutics Market Snippet by Dosage Form
- 2.1.3. Respiratory Syncytial Virus Therapeutics Market Snippet by Age Group
- 2.1.4. Respiratory Syncytial Virus Therapeutics Market Snippet by Distribution Channel
- 2.1.5. Respiratory Syncytial Virus Therapeutics Market Snippet by Country
- 2.1.6. Respiratory Syncytial Virus Therapeutics Market Snippet by Region
2.2. Competitive Insights

3. Respiratory Syncytial Virus Therapeutics Key Market Trends

3.1. Respiratory Syncytial Virus Therapeutics Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Respiratory Syncytial Virus Therapeutics Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Respiratory Syncytial Virus Therapeutics Market Opportunities
3.4. Respiratory Syncytial Virus Therapeutics Market Future Trends

4. Respiratory Syncytial Virus Therapeutics Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Respiratory Syncytial Virus Therapeutics Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Respiratory Syncytial Virus Therapeutics Market Landscape

6.1. Respiratory Syncytial Virus Therapeutics Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Respiratory Syncytial Virus Therapeutics Market - By Treatment Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Treatment Type, 2024 & 2032 (%)
- 7.1.2. Antiviral Drugs
- 7.1.3. Monoclonal Antibodies
- 7.1.4. Vaccines

8. Respiratory Syncytial Virus Therapeutics Market - By Dosage Form

8.1. Overview
- 8.1.1. Segment Share Analysis, By Dosage Form, 2024 & 2032 (%)
- 8.1.2. Oral
- 8.1.3. Injectable
- 8.1.4. Inhalation

9. Respiratory Syncytial Virus Therapeutics Market - By Age Group

9.1. Overview
- 9.1.1. Segment Share Analysis, By Age Group, 2024 & 2032 (%)
- 9.1.2. Infants & Young Children
- 9.1.3. Adults
- 9.1.4. Older Adults (65+ years)

10. Respiratory Syncytial Virus Therapeutics Market - By Distribution Channel

10.1. Overview
- 10.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
- 10.1.2. Hospitals & Clinics
- 10.1.3. Retail Pharmacies
- 10.1.4. Online Pharmacies

11. Respiratory Syncytial Virus Therapeutics Market- By Geography

11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
11.2. North America
- 11.2.1. Overview
- 11.2.2. Respiratory Syncytial Virus Therapeutics Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.2.8. The U.S.
  - 11.2.8.1. Overview
  - 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.8.3. U.S. Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.2.8.4. U.S. Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.2.8.5. U.S. Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.2.9. Canada
  - 11.2.9.1. Overview
  - 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.9.3. Canada Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.2.9.4. Canada Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.2.9.5. Canada Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.3. Europe
- 11.3.1. Overview
- 11.3.2. Respiratory Syncytial Virus Therapeutics Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.8. Germany
  - 11.3.8.1. Overview
  - 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.8.3. Germany Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.8.4. Germany Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.3.8.5. Germany Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.9. UK
  - 11.3.9.1. Overview
  - 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.9.3. UK Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.9.4. UK Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.3.9.5. UK Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.3.9.6. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.10. France
  - 11.3.10.1. Overview
  - 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.10.3. France Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.10.4. France Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.3.10.5. France Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.3.10.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.11. Italy
  - 11.3.11.1. Overview
  - 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.11.3. Italy Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.11.4. Italy Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.3.11.5. Italy Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.3.11.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.12. Spain
  - 11.3.12.1. Overview
  - 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.12.3. Spain Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.12.4. Spain Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.3.12.5. Spain Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.3.12.6. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.13. The Netherlands
  - 11.3.13.1. Overview
  - 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.13.3. The Netherlands Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.13.4. The Netherlands Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.3.13.5. The Netherlands Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.3.13.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.14. Sweden
  - 11.3.14.1. Overview
  - 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.14.3. Sweden Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.14.4. Sweden Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.3.14.5. Sweden Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.3.14.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.15. Russia
  - 11.3.15.1. Overview
  - 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.15.3. Russia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.15.4. Russia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.3.15.5. Russia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.3.15.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.16. Poland
  - 11.3.16.1. Overview
  - 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.16.3. Poland Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.16.4. Poland Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.3.16.5. Poland Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.3.17. Rest of Europe
  - 11.3.17.1. Overview
  - 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.17.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.3.17.4. Rest of the Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.3.17.5. Rest of the Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.3.17.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Respiratory Syncytial Virus Therapeutics Key Manufacturers in Asia Pacific
- 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.4.4. APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 11.4.5. APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 11.4.6. APAC Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
- 11.4.7. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.8. China
  - 11.4.8.1. Overview
  - 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.8.3. China Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.8.4. China Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.4.8.5. China Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.4.8.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.9. India
  - 11.4.9.1. Overview
  - 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.9.3. India Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.9.4. India Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.4.9.5. India Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.4.9.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.10. Japan
  - 11.4.10.1. Overview
  - 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.10.3. Japan Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.10.4. Japan Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.4.10.5. Japan Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.11. South Korea
  - 11.4.11.1. Overview
  - 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.11.3. South Korea Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.11.4. South Korea Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.4.11.5. South Korea Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.12. Australia
  - 11.4.12.1. Overview
  - 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.12.3. Australia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.12.4. Australia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.4.12.5. Australia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.13. Indonesia
  - 11.4.13.1. Overview
  - 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.13.3. Indonesia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.13.4. Indonesia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.4.13.5. Indonesia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.4.13.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.14. Thailand
  - 11.4.14.1. Overview
  - 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.14.3. Thailand Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.14.4. Thailand Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.4.14.5. Thailand Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.4.14.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.15. Philippines
  - 11.4.15.1. Overview
  - 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.15.3. Philippines Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.15.4. Philippines Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.4.15.5. Philippines Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.4.16. Rest of APAC
  - 11.4.16.1. Overview
  - 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.16.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.4.16.4. Rest of APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.4.16.5. Rest of APAC Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.5. Latin America (LATAM)
- 11.5.1. Overview
- 11.5.2. Respiratory Syncytial Virus Therapeutics Key Manufacturers in Latin America
- 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.5.4. LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 11.5.5. LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 11.5.6. LATAM Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
- 11.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.5.8. Brazil
  - 11.5.8.1. Overview
  - 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.8.3. Brazil Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.5.8.4. Brazil Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.5.8.5. Brazil Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.5.9. Mexico
  - 11.5.9.1. Overview
  - 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.9.3. Mexico Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.5.9.4. Mexico Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.5.9.5. Mexico Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.5.10. Argentina
  - 11.5.10.1. Overview
  - 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.10.3. Argentina Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.5.10.4. Argentina Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.5.10.5. Argentina Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.5.11. Colombia
  - 11.5.11.1. Overview
  - 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.11.3. Colombia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.5.11.4. Colombia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.5.11.5. Colombia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.5.12. Rest of LATAM
  - 11.5.12.1. Overview
  - 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.12.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.5.12.4. Rest of LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.5.12.5. Rest of LATAM Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa (MEA)
- 11.6.1. Overview
- 11.6.2. Respiratory Syncytial Virus Therapeutics Key Manufacturers in Middle East and Africa
- 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.6.4. MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 11.6.5. MEA Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
- 11.6.6. MEA Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
- 11.6.7. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.8. Saudi Arabia
  - 11.6.8.1. Overview
  - 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.8.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.6.8.4. Saudi Arabia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.6.8.5. Saudi Arabia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.9. United Arab Emirates
  - 11.6.9.1. Overview
  - 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.9.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.6.9.4. United Arab Emirates Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.6.9.5. United Arab Emirates Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.10. Israel
  - 11.6.10.1. Overview
  - 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.10.3. Israel Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.6.10.4. Israel Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.6.10.5. Israel Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.11. Turkey
  - 11.6.11.1. Overview
  - 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.11.3. Turkey Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.6.11.4. Turkey Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.6.11.5. Turkey Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.12. Algeria
  - 11.6.12.1. Overview
  - 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.12.3. Algeria Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.6.12.4. Algeria Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.6.12.5. Algeria Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.13. Egypt
  - 11.6.13.1. Overview
  - 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.13.3. Egypt Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.6.13.4. Egypt Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.6.13.5. Egypt Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 11.6.14. Rest of MEA
  - 11.6.14.1. Overview
  - 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.14.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 11.6.14.4. Rest of MEA Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
  - 11.6.14.5. Rest of MEA Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
  - 11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Respiratory Syncytial Virus Therapeutics Industry

12.1. Competitive Dashboard
- 12.1.1. Competitive Benchmarking
- 12.1.2. Competitive Positioning
12.2. Company Profiles
- 12.2.1. AstraZeneca plc
- 12.2.2. Sanofi S.A.
- 12.2.3. Pfizer Inc.
- 12.2.4. Moderna, Inc.
- 12.2.5. GSK plc
- 12.2.6. Merck & Co., Inc.
- 12.2.7. Johnson & Johnson
- 12.2.8. Novavax, Inc.
- 12.2.9. Bavarian Nordic A/S
- 12.2.10. Enanta Pharmaceuticals, Inc.
- 12.2.11. BioNTech SE
- 12.2.12. Meissa Vaccines, Inc.
- 12.2.13. Codagenix, Inc.
- 12.2.14. Alnylam Pharmaceuticals, Inc.
- 12.2.15. Vaxart, Inc.
- 12.2.16. Icosavax, Inc.

13. 360 Degree AnalystView

14. Appendix

14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us